AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction

Recruiting now · Phase 3 · Has a placebo group

Conditions studied: Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)

In brief

The purpose of this study is to assess the efficacy and safety of single injection dose of AURN001 compared with placebo in adult participants with corneal edema secondary to corneal endothelial dysfunction.

Key facts

Study ID

NCT07368959

Run by

Aurion Biotech

People needed

120

Starts

2026-02-19

Expected to finish

2028-01-01

Last updated by the study team

2026-05-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Investigational Site 2 — Mesa, Arizona, United States (enrolling)
• Investigational Site 6 — Little Rock, Arkansas, United States (enrolling)
• Investigational Site 9 — Fort Collins, Colorado, United States (enrolling)
• Investigational Site 7 — Atlanta, Georgia, United States (enrolling)
• Investigational Site 4 — Kansas City, Missouri, United States (enrolling)
• Investigational Site 11 — Leland, North Carolina, United States (enrolling)
• Investigational Site 5 — Winston-Salem, North Carolina, United States (enrolling)
• Investigational Site 3 — Cynwyd, Pennsylvania, United States (enrolling)
• Investigational Site 10 — Plymouth Meeting, Pennsylvania, United States (enrolling)
• Investigational Site 12 — Ladson, South Carolina, United States (enrolling)
• Investigational Site 8 — San Antonio, Texas, United States (enrolling)
• Investigational Site 1 — Spring, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.